‘Share­hold­ers de­serve bet­ter’: Mereo lays off em­ploy­ees, push­es back against lead stake­hold­er's shake­up pro­pos­als 

Mereo Bio­Phar­ma has faced a se­ries of board- and com­pa­ny-shift­ing re­quests from its main share­hold­er Rubric Cap­i­tal Man­age­ment in re­cent months, and the UK biotech is once again at­tempt­ing to put an end to the de­mands.

The Lon­don rare dis­ease and on­col­o­gy drug de­vel­op­er has laid off em­ploy­ees, with head­count and oth­er “pro­gram re­lat­ed and gen­er­al and ad­min­is­tra­tive cost re­duc­tions,” the com­pa­ny said in a let­ter to Rubric on Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER